MHRA Updates GCP Inspection Guidance for ICH E6(R3)
The MHRA GCP inspection guidance now reflects ICH E6(R3) and the UK’s 2026 trials reform, with a new computerised systems dossier and clear TMF access rules.
How Low Can They Go? Clinical Trial Success Rates
Clinical trial success rates have declined sharply over the past 20 years. This analysis examines what the data reveals about the drug approval rate and phase-by-phase attrition.
11 Clinical Trials Defining Pharmaceutical Strategy in 2026
We've mapped the competitive, regulatory, and commercial stakes of the top 11 clinical trials that have defined pharma strategy so far in 2026.
Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge
Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.
Psychedelic Drug Discovery Gets a New Preclinical Framework
Find out how psychedelic drug discovery is evolving through receptor pharmacology, behavioural science, and neuroplasticity to develop safer CNS therapeutics.
Google SensorFM: One Trillion Minutes of Wearable AI Data
Google SensorFM was pretrained on over one trillion minutes of wearable data. Discover what this AI foundation model could mean for digital health and pharma.